Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study

Rebecca L. Olin, MD, Caitrin Fretham, Marcelo C. Pasquini, MD, Mukta Arora, MD, Vijaya R. Bhatt, MD, Benjamin Derman, MDBA, Sergio A Giralt, MD, Li-Wen Huang, MD, Thuy T. Koll, MD, Sang Mee Lee, PhD, Richard J Lin, MD PhD, Linda Pang, MD, Uday Popat, MD, Daniel J. Weisdorf, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 4606.

https://doi.org/10.1182/blood-2019-123598

Published: 2019

Journal Articles

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Li-Wen Huang, MD, Chiung-Yu Huang, PhD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Catherine C. Smith, MD, Karin M. Gaensler, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Michael A. Steinman, MD, Rebecca L. Olin, MD

Blood (2018) 132 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2018-99-112025

Published: 2018

Journal Articles

High Prevalence and Incidence of Fractures in Patients Treated for Aggressive B-Cell Non-Hodgkin Lymphomas

Li-Wen Huang, MD, Dong Sun, MD PhD, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Thomas M Link, MD PhD, Thomas Lang, PhD, Charalambos Andreadis, MD MSCE

Blood (2017) 130 (Supplement 1): 4131.

https://doi.org/10.1182/blood.V130.Suppl_1.4131.4131

Published: 2017

Journal Articles

A Phase II, Open-Label Pilot Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined with G-CSF in 12 Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Lymphoma - an Interim Analysis

Gayatri Setia, B.S., Nabil Hagog, PhD, Bita Jalilizeinali, DNP, Sharon Funkhouser, R.N., Loretta Pierzchanowski, R.N., Fengshuo Lan, MD PhD, Theodore G. Gabig, MD, Bonnie Kiner-Strachan, MD, Karen Kelleher, Ming-Chu Hsu, PhD, Li-Wen Chang, Michael W. Schuster, MD

Blood (2015) 126 (23): 515.

https://doi.org/10.1182/blood.V126.23.515.515

Published: 2015

Journal Articles

TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial.

David T. Chung, Li-Wen Chang, Ying-Huey Huang, Cheng-Yuan Tsai, Ching-Hung Hsu, Chi-Hsin R. King, Judy H. Yuan, Chi-Feng Yen, Yu-Mai Chen, Yi Chin Lu, Ming-Chu Hsu, PhD

Blood (2009) 114 (22): 866.

https://doi.org/10.1182/blood.V114.22.866.866

Published: 2009

Journal Articles

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

Gary L Schieven, Rosemary Zhang, Sidney Pitt, Kelly McGlinchey, Krista Menard, Richard Smykla, Vojkan Susulic, Mei-Li Wen, Amy Wiebesiek, Robert Townsend, Francis Y. Lee

Blood (2009) 114 (22): 2198.

https://doi.org/10.1182/blood.V114.22.2198.2198

Published: 2009

Journal Articles

The TNF (−308A) polymorphism is associated with microchimerism in transfused trauma patients

Ryan M. Gill, Tzong-Hae Lee, Garth H. Utter, William F. Reed, Li Wen, Dan Chafets, Michael P. Busch

Blood (2008) 111 (7): 3880–3883.

https://doi.org/10.1182/blood-2007-08-107144

Published: 2008

Journal Articles

Effects of rmhTRAIL Combined with Daunorubicin in Inducing Apoptosis of Leukemia Cell Lines and Its Mechanism.

Xuejun Zhang, Li Wen, Fuxu Wang, Ling Pan, Jianmin Luo, Zuoren Dong

Blood (2006) 108 (11): 1986.

https://doi.org/10.1182/blood.V108.11.1986.1986

Published: 2006

Journal Articles

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

Francis Y. Lee, PhD, Mei-Li Wen, M.Sc., Amy Camuso, B.Sc, Stephen Castenada, B.Sc, Krista Fager, M.Sc., Christine Flefleh, B.Sc, Ivan Inigo, B.Sc, Roger Luo, PhD, David Kan, B.Sc, Veeraswamy Manne, PhD, Kelly McGlinchey, B.Sc, Richard Smykla, B.Sc, Roberto Weinmann, PhD, Robert Kramer, PhD

Blood (2005) 106 (11): 1993.

https://doi.org/10.1182/blood.V106.11.1993.1993

Published: 2005

Journal Articles

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Francis Y. Lee, PhD, Mei-Li Wen, M.Sc., Rajeev Bhide, PhD, Amy Camuso, B.Sc, Stephen Castenada, B.Sc, Krista Fager, B.Sc, Christine Flefleh, B.Sc, Ivan Inigo, B.Sc, David Kan, B.Sc, Roger Luo, PhD, Kelly McGlinchey, B.Sc, Richard Smykla, B.Sc, Robert Wild, PhD, Robert Borzilleri, PhD, Louis Lombardo, PhD

Blood (2005) 106 (11): 1994.

https://doi.org/10.1182/blood.V106.11.1994.1994

Published: 2005

Journal Articles

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

Feng Roger Luo, Ph.D., Zheng Yang, Ph.D., Amy Camuso, B.S., Richard Smykla, B.S., Stephen Castenada, B.S., Christine Flefleh, B.S., Krista Fager, M.S., Ivan Inigo, B.S., David Kan, B.S., Kelly McGlinchey, B.S., Mei-Li Wen, M.S., Robert Wild, Ph.D., Robert Borzilleri, Ph.D., Louis Lombardo, Ph.D., Robert Kramer, Ph.D., Francis Y. Lee, Ph.D.

Blood (2004) 104 (11): 1987.

https://doi.org/10.1182/blood.V104.11.1987.1987

Published: 2004

Journal Articles

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

Robert Wild, Ph.D., Stephen Castaneda, B.S., Christine Flefleh, B.S., Krista Fager, B.S., Ivan Inigo, B.S., David Kan, B.S., Richard Smykla, B.S., Amy Camuso, B.S., Kelly McGlinchey, B.S., Mei-Li Wen, B.S., Feng Roger Luo, Ph.D., Robert Borzilleri, Ph.D., Louis Lombardo, Ph.D., Robert Kramer, Ph.D., Francis Y. Lee, Ph.D.

Blood (2004) 104 (11): 1988.

https://doi.org/10.1182/blood.V104.11.1988.1988

Published: 2004

NARROW

Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

High Prevalence and Incidence of Fractures in Patients Treated for Aggressive B-Cell Non-Hodgkin Lymphomas

A Phase II, Open-Label Pilot Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined with G-CSF in 12 Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Lymphoma - an Interim Analysis

TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial.

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

The TNF (−308A) polymorphism is associated with microchimerism in transfused trauma patients

Effects of rmhTRAIL Combined with Daunorubicin in Inducing Apoptosis of Leukemia Cell Lines and Its Mechanism.

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only